Syndax Pharmaceuticals
SNDX
215 hedge funds and large institutions have $1.3B invested in Syndax Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 89 increasing their positions, 60 reducing their positions, and 29 closing their positions.
208% more call options, than puts
Call options by funds: $19.4M | Put options by funds: $6.29M
48% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 60
24% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 29
10.31% more ownership
Funds ownership: 104.55% → 114.85% (+10%)
2% more funds holding
Funds holding: 210 → 215 (+5)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
24% less capital invested
Capital invested by funds: $1.71B → $1.3B (-$418M)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$75.7M |
| 2 |
Goldman Sachs
New York
|
+$74.3M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$45.8M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$27.4M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$24M |
Top Sellers
| 1 |
EP
Eversept Partners
New York
|
-$64.4M |
| 2 |
O
OrbiMed
New York
|
-$37.1M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$27.6M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$18M |
| 5 |
CC
Commodore Capital
New York
|
-$17M |
SNDX Hedge Fund Activity: Q4 2024 in Review
215 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2024, worth a combined $1.3B — down 24% from $1.71B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new SNDX positions and 29 closed out — a net gain of 7 holders — while 89 added to existing stakes and 60 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $75.7M. The largest seller was Eversept Partners, cutting an estimated $64.4M.
- 215 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2024, up from 210 in Q3 2024.
- Funds reported $1.3B of Syndax Pharmaceuticals stock for Q4 2024, down 24% quarter-over-quarter.
- 36 funds opened new Syndax Pharmaceuticals positions in Q4 2024 and 29 closed out, a net change of +7 holders.
- The largest Syndax Pharmaceuticals buyer in Q4 2024 was Morgan Stanley, an estimated $75.7M added.
- The largest Syndax Pharmaceuticals seller in Q4 2024 was Eversept Partners, an estimated $64.4M sold.
Based on aggregated 13F filings for Q4 2024.